Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azd2811 + durvalumab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AZD2811 + durvalumab is an investigational combination therapy composed of AZD2811, a nanoparticle-formulated, potent, and selective inhibitor of Aurora kinase B, and durvalumab, a human monoclonal antibody targeting PD-L1. AZD2811 inhibits Aurora kinase B, disrupting mitotic progression and promoting apoptosis in tumor cells. Durvalumab blocks the interaction of PD-L1 with PD-1 and CD80, thereby enhancing antitumor immune responses by promoting T-cell activity. The combination is being studied primarily as maintenance therapy after induction with platinum-based chemotherapy combined with durvalumab for the first-line treatment of extensive stage small-cell lung cancer (ES-SCLC)[1][3][5].
- Brand names
- Imfinzi + AZD2811
- Other names
- AZD2811 and durvalumab combinationAZD-2811 and durvalumab combinationAZD 2811 and durvalumab combinationAZD2811-np and durvalumabAZD-2811-np and durvalumabAZD 2811-np and durvalumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)AURKB (Aurora kinase B)
Beyond the preview
Go deeper on azd2811 + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azd2811 + durvalumab.